Advertisement

Ernährungstherapie von angeborenen Stoffwechsel-und Speichererkrankungen

  • H. Böhles
  • J. Bargon
  • J. Stein

Zusammenfassung

Schädigungen, die im Rahmen angeborener Stoffwechselerkrankungen auftreten, sind entweder Folge der toxischen Wirkung eines pathologisch erhöhten Metaboliten des Intermediärstoffwechsels oder die Folge eines durch den Defekt entstandenen Mangels. Die Behandlungsprinzipien sind dabei immer:
  • Verhinderung der Anhäufung toxischer Substrate und Metaboliten.

  • Zufuhr eines limitierenden Metaboliten nach einem metabolischen Block.

  • Zufuhr eines Metaboliten, dessen Fehlen eine eigene Problematik verursacht.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Acosta PB, Gross KC (1995) Hidden sources of galactose in the environment. Eur J Pediatr 154:S87–S92PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson LA, Hakojarvi SL, Boudreaus SK (1998) Zinc acetate treatment in Wilson’s disease. Ann Pharmacother 32:78–87PubMedCrossRefGoogle Scholar
  3. 3.
    Bachmann C (1984) Treatment of congenital hyperammonemias. Enzyme 32:56–64PubMedGoogle Scholar
  4. 4.
    Bachmann C, Colombo JP (1983) Increased trypotphan uptake into the brain in hyper-ammonemia. Life Sci 33:2417–2424PubMedCrossRefGoogle Scholar
  5. 5.
    Bacon BR (1997) Diagnosis and management of hemochromatosis. Gastroenterology 113:995–999PubMedCrossRefGoogle Scholar
  6. 6.
    Bacon BR, Powell LW, Adams PC et al. (1999) Molecular medicine and hemochromatosis. Gastroenterology 116:193–958PubMedCrossRefGoogle Scholar
  7. 7.
    Ballmann M, Smaczny C (1998) CF-Manual. Solvay Arzneimittel GmbH (Hrsg.) Werbedruck Lönneker, StadtoldendorfGoogle Scholar
  8. 8.
    Bargon J, Rickmann J (2001) Mukoviszidose — eine multidisplinäre Herausforderung. Aktuel Ernaehr Med 26:90–95CrossRefGoogle Scholar
  9. 9.
    Bargon J, Stein J, Dietrich CF et al. (1999) Gastrointestinale Komplikationen erwachsener Patienten mit zystischer Fibrose.Z Gastroenterol 37:739–749Google Scholar
  10. 10.
    Berry GT, Nissim I, Lin Z et al. (1995) Endogenous synthesis of galactose in normal men and patients with hereditary galactosemia. Lancet 346:1073–1074PubMedCrossRefGoogle Scholar
  11. 11.
    Binkley NC, Suttie JW (1995) Vitamin K nutrition and osteoporosis. J. Nutrition 125:1812–1821Google Scholar
  12. 12.
    Bougnères PF, Saudubray JM, Marsac C et al. (1981) Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency. J Pediatr 98:742–746PubMedCrossRefGoogle Scholar
  13. 13.
    Bulaj ZJ, Philipps JD, Ajioka RS et al. (2000) Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95:1565–1571PubMedGoogle Scholar
  14. 14.
    Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ (1996) Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur J Pediatr 155 (Suppl 1): 33–38CrossRefGoogle Scholar
  15. 15.
    Buxton PC, Jähnke RWO, Keady S (1994) Degradation of glucose in the presence of electrolytes during heat sterilisation. Eur J Pharm Biopharm 40:172–177Google Scholar
  16. 16.
    Cummings JH (1981) Short-chain fatty acids in the human colon. Gut 22:763–769PubMedCrossRefGoogle Scholar
  17. 17.
    Davis W, Chowrimootoo GFE, Seymour CA (1996) Defective biliary copper excretion in Wilson’s disease:the role of caeruloplasmin. Eur J Clin Invest 25:893–901CrossRefGoogle Scholar
  18. 18.
    Dixon MA, Leonard JV (1992) Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Childh 67:1387–1391PubMedCrossRefGoogle Scholar
  19. 19.
    Doss MO (1997) Hepatische Porphyrien. Med Klein 92:745–746CrossRefGoogle Scholar
  20. 20.
    Duran M, Tielens AGM, Wadman SK, Stigter JCM, Kleijer W (1978) Effects of thiamine in a patient with a variant form of branched-chain ketoaciduria. Acta Paediatr Scand 67:367–372PubMedCrossRefGoogle Scholar
  21. 21.
    Eisensmith RC, Martinez DR, Kuzmin AI (1996) Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous Southeastern US population. Pediatr 97:512–516Google Scholar
  22. 22.
    Freedman SD, Katz MH, Parker EM et al: (1999) A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/-mice. Proc Natl Acad Sci USA 96:13995–14000PubMedCrossRefGoogle Scholar
  23. 23.
    Frei B (1999) On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction. Proc Soc Exp Biol Med 222: 196–204PubMedCrossRefGoogle Scholar
  24. 24.
    Gitzelmann R, Baerlocher K (1973) Vorteile und Nachteile der Fructose in der Nahrung. Paediatr Fortbildk Praxis 37:40–45Google Scholar
  25. 25.
    Glasgow AM, Engel AG, Bier DM et al. (1983) Hypoglycemia, hepatic deficiency and long-chain acylcarnitine excess responsive to medium chain triglyceride diet. Pediatr Res 17:319–326PubMedCrossRefGoogle Scholar
  26. 26.
    Greener M (2000) Fatty acid imbalance might lead to novel treatments for CF. Mol Med Today 6:47–48PubMedCrossRefGoogle Scholar
  27. 27.
    Hermann T, Smolarek C, Gehrke S, Stremmel W (1999) Hämochroma-tose und Morbus Wilson. Internist 40:513–521CrossRefGoogle Scholar
  28. 28.
    Kaltwasser JP, Caspary WF (2000) Hämochromatose. In: Caspary WF, Leuschner U, Zeuzem S (Hrsg) Therapie von Leber- und Gallekrankheiten. Springer, Berlin Heidelberg New York Tokio, S. 79–90Google Scholar
  29. 29.
    Kaltwasser JP, Werner E, Schalk K et al. (1998) Clinical trial on the effect of regular tea drinking on iron accumulation in genetic hemochromatosis. Gut 43:699–704PubMedCrossRefGoogle Scholar
  30. 30.
    Kaufman FR, Loro ML, Azen C, Wenz E, Gilsanz V (1993) Effect of hypogonadism and deficient calcium intake on bone density in patients with galactosemia. J Pediatr 123:365–370PubMedCrossRefGoogle Scholar
  31. 31.
    Keicher U, Koletzko B, Reinhardt D (1995) Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur J Clin Invest 25:915–919PubMedCrossRefGoogle Scholar
  32. 32.
    Koletzko B, Bachmann C, Wendel U (1990) Antibiotic therapy for improvement of metabolic control in methylmalonic aciduria. J Pediatr 117:99–101PubMedCrossRefGoogle Scholar
  33. 33.
    Koletzko S, Koletzko B (1993) Zystische Fibrose-Normalernährung oder Ernährungstherapie. In: Koletzko B (Hrsg) Ernährung chronisch kranker Kinder und Jugendlicher. Springer, Berlin Heidelberg New York Tokio, S. 167–190CrossRefGoogle Scholar
  34. 34.
    Koletzko S, Koletzko B, Reinhardt D 1994) Aktuelle Aspekte der Ernährungstherapie bei zystischer Fibrose. Monatsschr Kinderheilkd 142: 432–445Google Scholar
  35. 35.
    Köstler E, Doss MO (1995) Porphyria cutanea tarda (chronische hepatische Porphyrie). Dtsch Med Wochenschr 120:1405–1410PubMedCrossRefGoogle Scholar
  36. 36.
    Krebs NF, Westcott JE, Arnold TD et al. (2000) Abnormalities in zinc homeostasis in young infants with cystic fibrosis. Pediatr Res 48:256–261PubMedCrossRefGoogle Scholar
  37. 37.
    Lambert JP (2000) Osteoporosis: A new challenge in cystic fobrosis. Pharmacotherapy 20:34–51PubMedCrossRefGoogle Scholar
  38. 38.
    Lanng S, Thorsteinsson B, Nerup J et al. (1994) Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 83:849–853PubMedCrossRefGoogle Scholar
  39. 39.
    Laursen EM, Molgaard C, Michaelsen KF et al.(1999) Bone mineral status in 134 patients with cystic fibrosis. Arch Dis Child 81:235–240PubMedCrossRefGoogle Scholar
  40. 40.
    Levy HL, Waisbren SE, Lobbregt D et al. (1994) Maternal mild hyper-phenylalaninemia: an international survey of offspring outcome. Lancet 344:1589–1594PubMedCrossRefGoogle Scholar
  41. 41.
    Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED (1984) Neurologic outcome in children with inborn errors of urea synthesis. N Engl J Med 310:1500–1505PubMedCrossRefGoogle Scholar
  42. 42.
    Naughten ER, Jenkins J, Francis DEM, Leonard JV (1982) Outcome of maple syrup urine disease. Arch Dis Childh 57:918–921PubMedCrossRefGoogle Scholar
  43. 43.
    Niederau C, Nieserau CM, Lange S et al. (1998) Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 128:337–342PubMedGoogle Scholar
  44. 44.
    Ott SM, Aitken ML (1998) Osteoporosis in patients with cystic fibrosis. Cystic Fibrosis 19:555–566Google Scholar
  45. 45.
    Percival SS, Bowser E, Wagner M (1995) Reduced copper enzyme activities in blood cells of children with cystic fibrosis. Am J Clin Nutr 62:633–663PubMedGoogle Scholar
  46. 46.
    Portal B, Richard MJ, Coudray C et al. (1995) Effect of double-blind cross-over selenium supplementation on lipid peroxidation markers in cystic fibrosis patients. Clin Chim Acta 234:137–146PubMedCrossRefGoogle Scholar
  47. 47.
    Robinson P (2001) Nutritional status and requirements in cystic fibrosis. Clin Nutr 20:81–86CrossRefGoogle Scholar
  48. 48.
    Sahm SW, Caspary WF (2000) Porphyrien. In: Caspary WF, Leuschner U, Zeuzem S (Hrsg) Therapie von Leber- und Gallekrankheiten. Springer, Berlin Heidelberg New York Tokio, S. 121–134Google Scholar
  49. 49.
    Sallan SE, Cotton D (1969) Peritoneal dialysis in marple syrup urine disease. Lancet II: 1423CrossRefGoogle Scholar
  50. 50.
    Sassa S, Kappas A (2000) Molecular aspects of inherited porphyrias. J Intern Med 247:169–178PubMedCrossRefGoogle Scholar
  51. 51.
    Scriver CR, Mackenzie S, Clow CL, Delvin E (1971) Thiamine-responsive maple-syrup- urine disease. Lancet 1:310–312PubMedCrossRefGoogle Scholar
  52. 52.
    Sewell A, Mosandl A, Böhles H (1999) False diagnosis of maple syrup urine disease owing to ingestion of herbal tea. N Engl J Med 341:769PubMedCrossRefGoogle Scholar
  53. 53.
    Sirtori CR, Pazzucconi F, Colombo L et al. (1999) Double-blind study of the addition of high-protein soya milk vs. cow’s milk to the diet of patients with severe hypercholesterinaemia and resistance to or intolerance of statins. Br J Nutr 82:91–96PubMedGoogle Scholar
  54. 54.
    Smith I, Beasley MG, Ades AE (1991) Effect of intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch Dis Child 65:311–316CrossRefGoogle Scholar
  55. 55.
    Smolarek C, Stremmel W (1999) Therapie des Morbus Wilson. Z Gastroenterol 37:293–300PubMedGoogle Scholar
  56. 56.
    Snyderman SE (1976) Branched chain ketoaciduria (maple syrup urine disease). Clin Perinatol 3:41–52PubMedGoogle Scholar
  57. 57.
    Stanley CA, Hale DE, Berry GT et al. (1992) A deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 327:19–23PubMedCrossRefGoogle Scholar
  58. 58.
    Steinkamp K (2001) Energieumsatz bei Mukoviszidose. Aktuelle Ernährungsmed 26:85–89CrossRefGoogle Scholar
  59. 59.
    Teixeira SR, Potter SM, Weigel R et al. (2000) Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipopro-teins in moderately hypercholesterinemic men. Am J Clin Nutr 71: 1077–1084PubMedGoogle Scholar
  60. 60.
    Thompson GN, Butt W, Shann FA et al. (1991) Continuous venovenous hemofiltration in the management of acute decompensation in inborn errors of metabolism. J Pediatr 118:879–884PubMedCrossRefGoogle Scholar
  61. 61.
    Thompson GN, Walter JH, Bresson JL (1990) Sources of propionate in inborn errors of propionate metabolism. Metabolism 39:1133–1137PubMedCrossRefGoogle Scholar
  62. 62.
    Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM (1988) Primary carnitine deficiency due toa failure of carnitine transport in kidney, muscle and fibroblasts. N Engl J Med 319:1331–1336PubMedCrossRefGoogle Scholar
  63. 63.
    v. Arnim U, Caspary WF (2000) Morbus Wilson. In: Caspary WF, Leuschner U, Zeuzem S (Hrsg) Therapie von Leber- und Gallekrankheiten. Springer, Berlin Heidelberg New York Tokio, S. 91–99Google Scholar
  64. 64.
    Waisman HA, Smith BA, Brown ES, Gerritsen T (1972) Treatment of branched chain ketoaciduria (BCKA) during actue illness. Clin Pediatr 11:360–364CrossRefGoogle Scholar
  65. 65.
    Walter JH, Collins JE, Leonard JV (1999) Recommendations for the management of galactosemia. Arch Dis Child 80:93–96PubMedCrossRefGoogle Scholar
  66. 66.
    Walter JH, Wraith JE, Cleary MA (1995) Absence of acidosis in the initial presentation of propionic acidemia. Arch Dis Child Fetal Neonatol 72: F 197–199CrossRefGoogle Scholar
  67. 67.
    Wendel U, Langenbeck U, Lombeck I, Bremer HJ (1982) Maple syrup urine disease — Therapeutic use of insulin in catabolic states. Eur J Pediatr 139:172–175PubMedCrossRefGoogle Scholar
  68. 68.
    Winklhofer-Roob BM (2000) Cystic fibrosis: nutritional status and mic-ronutrients. Curr Opin Clin Nutr Metab Care 3:293–297PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • H. Böhles
  • J. Bargon
  • J. Stein

There are no affiliations available

Personalised recommendations